[Jopamidol, a non-ionic x-ray contrast medium--tolerance from a neurological viewpoint].
A double-blind trial was carried out in 80 patients, whereby jopamidol, the first stabilized non-ionic contrast medium, and meglumine iodamine were compared in 40 patients undergoing cranial computed tomography and 40 patients subjected to cerebral angiography. There was no difference in the quality of the radiographs. Jopamidol was better tolerated and caused significantly fewer side effects or complications than meglumine iodamine. Our evidence suggests that jopamidol has significant advantages over currently employed contrast media for cranial computed tomography and cerebral angiography.
D000293:Adolescent; D000328:Adult; D000368:Aged; D001927:Brain Diseases / Q000000981:diagnostic imaging; D002533:Cerebral Angiography; D003287:Contrast Media / Q000008:administration & dosage; D004361:Drug Tolerance; D005260:Female; D005767:Gastrointestinal Diseases / Q000139:chemically induced; D006801:Humans; D007451:Iodamide / Q000009:adverse effects; D007479:Iopamidol; D007483:Iothalamic Acid / Q000009:adverse effects / Q000031:analogs & derivatives*; D008297:Male; D008875:Middle Aged; D012886:Skull / Q000000981:diagnostic imaging; D013651:Taste Disorders / Q000139:chemically induced; D014057:Tomography, X-Ray Computed; D014581:Urticaria / Q000139:chemically induced
D003287:Contrast Media; D007483:Iothalamic Acid; D007451:Iodamide; D007479:Iopamidol
Jopamidol, ein nichtionisches Röntgenkontrastmittel--Verträglichkeit aus der Sicht des Neurologen.